[IPO] SBioMedics "Leading the Market with Blockbuster Cell Therapy Development"

Specialized regenerative medicine company S-Biomedics, focused on cell therapy products, held an IPO press conference on the 8th in Yeouido and announced its growth strategy post-listing. S-Biomedics is scheduled to enter the KOSDAQ market next month through a technology-specialized listing.

Kang Se-il, CEO of S-Biomedics, is introducing the company at a press conference for KOSDAQ listing held on the 8th in Yeouido, Seoul. / Photo by S-Biomedics

S-Biomedics is researching and developing ‘disease-specific cell therapies’ that overcome the limitations of existing cell therapy products. Among its two core platform technologies, TED (International Standardized Embryonic Stem Cell Differentiation Technology) can safely and efficiently differentiate disease-specific cells, while FECS™ (3D Functional Spheroid Implementation Technology) enables the development of spheroid therapeutics composed of functionally enhanced cells. Based on these technologies, the company holds eight pipelines, five of which?TED-A9 (Parkinson’s disease treatment), TED-N (spinal cord injury treatment), FECS-Ad (critical limb ischemia treatment), FECS-DF (eye wrinkle improvement), and CureSkin (depressed acne scar treatment)?are currently in clinical stages.

S-Biomedics’ confidence in clinical success stems from its robust technological capabilities. Regarding its two core platform technologies and related key and derivative pipelines, the company has filed a total of 132 patents in major global bio markets including Korea, the United States, Europe, and Japan, with 87 patents already registered. By generating strong technological IP during R&D, the company secures rights and explores potential technology exports in the future.

Competing with global top-tier companies, S-Biomedics emphasized the likelihood of clinical success. CEO Kang Se-il of S-Biomedics stated, “We have achieved meaningful results in core pipeline research such as critical limb ischemia, spinal cord injury, and Parkinson’s disease,” adding, “Our world’s first stem cell spheroid-based critical limb ischemia treatment is in clinical phase 2a and demonstrates superior efficacy in vascular regeneration, inflammation suppression, and pain reduction compared to existing adult cell therapies.”

He continued, “Our embryonic stem cell-derived spinal cord injury treatment is the second worldwide clinical trial after a U.S. biotech company, and preclinical animal studies have proven improvements in motor function and sensory and motor evoked potentials following transplantation of PSA-NCAM positive neural progenitor cells.”

Regarding the embryonic stem cell-derived Parkinson’s disease treatment, which holds the title of ‘Asia’s first clinical approval,’ he said, “We have confirmed the high-yield production and mass manufacturing capability of A9-DPC (dopaminergic neural progenitor cells), and transplantation of these cells demonstrated sustained improvement in dopamine activity compared to controls in primate models, verifying the therapeutic effect for Parkinson’s disease.” He added, “Only three groups worldwide, including our company, are developing Parkinson’s disease-specific A9 cells.”

In the mid to long term, S-Biomedics plans to actively pursue domestic commercialization and overseas technology business (licensing) through successful clinical development of its core pipelines. The company explained that short-term revenue generation is realized through its subsidiary Esteparm, which researches and develops beauty, plastic surgery, pharmaceuticals, and medical devices. Esteparm has established an in-house system from actual manufacturing to commercialization, including self-produced HA (hyaluronic acid) fillers, and continues to show sales growth through a global distribution network spanning over 1,500 domestic partner hospitals and 25 countries overseas. Esteparm’s sales amounted to 12 billion KRW as of 2022.

CEO Kang Se-il stated, “We want to invest the funds raised through this public offering into clinical trials to bring hope to patients and families suffering from intractable diseases,” and added, “We will accelerate clinical research to lead the disease-specific cell therapy market and repay investors with results as a ‘blockbuster cell therapy product.’”